Literature DB >> 9517756

Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981-1996.

M M Ward1, J F Fries.   

Abstract

OBJECTIVE: To describe changes in antirheumatic medication use by patients with rheumatoid arthritis (RA) over the 15 years 1981 to 1996.
METHODS: Medication use was ascertained every 6 months by mailed Health Assessment Questionnaire in a cohort of patients recruited from the local community (n = 305; mean duration of RA at study entry 14.2 yrs). Patients were treated by 53 rheumatologists and over 200 other physicians during the study. The proportions of patients treated with nonsteroidal antiinflammatory drugs (NSAID), disease modifying antirheumatic drugs (DMARD), prednisone, intraarticular corticosteroids, and analgesics were determined in serial cross sectional analyses, and trends in medication use over time were analyzed using linear regression.
RESULTS: From 1981 to 1996, the proportion of patients treated with DMARD increased from 32 to 47% (average increase 1.06% each year; p < 0.0001), while the proportion treated with NSAID decreased from 86 to 76% (average decrease 0.57% each year; p < 0.0001). The proportion of patients treated with prednisone remained between 30 and 40%, with a trend toward increasing use over time (average increase 0.2% each year; p = 0.05). In contrast, the proportion treated with intraarticular corticosteroids decreased from 14.4 to 6.7% (average decrease 0.46% each year; p < 0.0001). In 1996, the most prevalent patterns of medication use were the use of NSAID alone (24.4%), use of an NSAID and DMARD (16.3%), and use of an NSAID, DMARD, and prednisone (12.2%). Use of an NSAID as the only antirheumatic medication decreased over time, and the use of DMARD in combination with other medications increased.
CONCLUSION: The proportion of patients with RA treated with DMARD increased substantially from 1981 to 1996. This change in practice occurred during the time in which the concept of inverting the traditional therapeutic pyramid became popular, and may reflect a translation among clinicians of the philosophy of "early DMARD use" to "consistent DMARD use," even among patients with RA of moderate or longstanding duration.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9517756

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  17 in total

1.  Contribution of chronic conditions to aggregate changes in old-age functioning.

Authors:  V A Freedman; L G Martin
Journal:  Am J Public Health       Date:  2000-11       Impact factor: 9.308

2.  Impact of tight control strategy on rheumatoid arthritis in Sarawak.

Authors:  Cheng Lay Teh; Jin Shyan Wong
Journal:  Clin Rheumatol       Date:  2010-10-01       Impact factor: 2.980

3.  Was there compression of disability for older Americans from 1992 to 2003?

Authors:  Liming Cai; James Lubitz
Journal:  Demography       Date:  2007-08

4.  Why is late-life disability declining?

Authors:  Robert F Schoeni; Vicki A Freedman; Linda G Martin
Journal:  Milbank Q       Date:  2008-03       Impact factor: 4.911

5.  Health and functioning among baby boomers approaching 60.

Authors:  Linda G Martin; Vicki A Freedman; Robert F Schoeni; Patricia M Andreski
Journal:  J Gerontol B Psychol Sci Soc Sci       Date:  2009-03-18       Impact factor: 4.077

6.  Trends in disability and related chronic conditions among people ages fifty to sixty-four.

Authors:  Linda G Martin; Vicki A Freedman; Robert F Schoeni; Patricia M Andreski
Journal:  Health Aff (Millwood)       Date:  2010-04       Impact factor: 6.301

Review 7.  A review of the direct costs of rheumatoid arthritis: managed care versus fee-for-service settings.

Authors:  D P Lubeck
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 8.  A risk-benefit assessment of intra-articular corticosteroids in rheumatic disorders.

Authors:  J A Hunter; T H Blyth
Journal:  Drug Saf       Date:  1999-11       Impact factor: 5.606

9.  Preference, satisfaction and usability of subcutaneously administered methotrexate for rheumatoid arthritis or psoriatic arthritis: results of a postmarketing surveillance study with a high-concentration formulation.

Authors:  Frank Striesow; Andreas Brandt
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-02       Impact factor: 5.346

Review 10.  Measuring the effects of medication use on health-related quality of life in patients with rheumatoid arthritis. A review.

Authors:  M B Nichol; A S Harada
Journal:  Pharmacoeconomics       Date:  1999-11       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.